Merck speeds its KRAS into the colorectal front line
The move follows promising but early data presented at ASCO.
ASCO 2025 preview – KRAS challengers assemble
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
FDA red and green lights: April 2025
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
Merck and Sanofi sound the alarm for ILT inhibition
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
FDA red and green lights: January 2025
AstraZeneca bags three of the month’s four oncology approvals.
A Leap into the subgroups
On a wing and a prayer Leap heads for phase 3.
ASCO-GI – a second colorectal win for Bristol's combo
Opdivo and Yervoy succeed again, but the US path remains unclear.
